"Sales in 2015 of its flagship product Axiron, a testosterone replacement therapy, missed our expectations. We believe future sales may not meet our targets. We advised to sell in 2015 and retain our advice. While ACR may present a speculative opportunity, we would want to see more encouraging data and a technical reversal of its stock before upgrading our view."
I should not be bashing this stock. I wish I could think of a counter positive argument. As @mwilson25 said: what are the management saying? Actually what are they doing? Can anyone can anything that will counter what Simon Hermann. I do not want "Simon is a complete $#@$#@$" or "Simon is an absolute genius, etc etc". He is a professional and he is entitled to promote his opinion. I just want a positive counter argument.
